Option Therapeutics Inc. Sample Contracts
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • March 16th, 2026 • Option Therapeutics Inc. • Pharmaceutical preparations • Delaware
This Patent Assignment Agreement (this “Agreement”), dated as of [•], 2026 (the “Effective Date”), is by and between BioVie Inc., a Nevada corporation, having an office at 680 W Nye Lane, Suite 204, Carson City, Nevada 89703 (“Assignor”) and Option Therapeutics Inc., a Delaware corporation, having an office at 680 W Nye Lane, Suite 204, Carson City, Nevada 89703 (“Assignee”).
FORM OF SEPARATION AGREEMENT BY AND BETWEEN BIOVIE INC. AND OPTION THERAPEUTICS INC. DATED AS OF [—], 2026Separation Agreement • March 16th, 2026 • Option Therapeutics Inc. • Pharmaceutical preparations • Delaware
This SEPARATION AGREEMENT, dated as of [—], 2026 (this “Agreement”), is made and entered into by and between BIOVIE INC., a Nevada corporation (“BioVie”), and OPTION THERAPEUTICS INC., a Delaware corporation (“SpinCo”). BioVie and SpinCo are referred to together as the “Parties” and individually as a “Party.” Capitalized terms used herein shall have the respective meanings assigned to them in Article I or elsewhere in this Agreement.
INTELLECUTAL PROPERTY RIGHTS AGREEMENTIntellectual Property Rights Agreement • March 16th, 2026 • Option Therapeutics Inc. • Pharmaceutical preparations
This Intellectual Property Rights Agreement (“Agreement-) is made by and between DOCUCHEM SLU, a corporation duly organized under and pursuant to the laws of Spain having its principle place of business at Edifici Giroempren, Laboratori A.0.07 C/ Pic de Peguera, 11 17003 Girona. Spain (“DOCUCHEM”), and BioVie, Inc., a Nevada Corporation, and having its principal place of business at 11601 Wilshire Blvd, Suite 1100, Los Angeles, CA, USA (“BIOVIE”) (collectively “the Parties”),
TECHNOLOGY TRANSFER AGREEMENTTechnology Transfer Agreement • March 16th, 2026 • Option Therapeutics Inc. • Pharmaceutical preparations
In this TECHNOLOGY TRANSFER AGREEMENT (the “Agreement”), made and entered into as of the 25th day of July, 2016 (“Effective Date”), by and among BioVie Inc. (“BioVie”) having a place of business at 100 Cummings Center, Suite 247-C, Beverly, Massachusetts 01915, and the University of Padova (a/k/a Universita degli Studi di Padova), an Italian University (“University”) having a place of business at Via 8 febbraio 2, 35122 Padova, Italy, the parties hereby agree as follows:
FORM OF MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • March 16th, 2026 • Option Therapeutics Inc. • Pharmaceutical preparations • New York
This MANAGEMENT SERVICES AGREEMENT (this “Agreement”) is made and entered into as of [•], 2026 by and between Option Therapeutics Inc., a Delaware corporation (“Service Recipient”), and BioVie Inc., a Nevada corporation (“Parent”), effective as of completion of the Separation (as defined below) or such other date as Service Recipient and Parent may mutually agree upon in writing (the “Effective Time”). Service Recipient and Parent shall be referred to collectively as the “Parties” and, individually, as a “Party”.
TECHNOLOGY TRANSFER AGREEMENTTechnology Transfer Agreement • January 26th, 2026 • Option Therapeutics Inc. • Pharmaceutical preparations
In this TECHNOLOGY TRANSFER AGREEMENT (the “Agreement”), made and entered into as of the 25th day of July, 2016 (“Effective Date”), by and among BioVie Inc. (“BioVie”) having a place of business at 100 Cummings Center, Suite 247-C, Beverly, Massachusetts 01915, and the University of Padova (a/k/a Universita degli Studi di Padova), an Italian University (“University”) having a place of business at Via 8 febbraio 2, 35122 Padova, Italy, the parties hereby agree as follows:
FORM OF SEPARATION AGREEMENT BY AND BETWEEN BIOVIE INC. AND OPTION THERAPEUTICS INC. DATED AS OF [—], 2025Separation Agreement • January 26th, 2026 • Option Therapeutics Inc. • Pharmaceutical preparations • Delaware
This SEPARATION AGREEMENT, dated as of [—], 2025 (this “Agreement”), is made and entered into by and between BIOVIE INC., a Nevada corporation (“BioVie”), and OPTION THERAPEUTICS INC., a Delaware corporation (“SpinCo”). BioVie and SpinCo are referred to together as the “Parties” and individually as a “Party.” Capitalized terms used herein shall have the respective meanings assigned to them in Article I or elsewhere in this Agreement.
INTELLECUTAL PROPERTY RIGHTS AGREEMENTIntellectual Property Rights Agreement • January 26th, 2026 • Option Therapeutics Inc. • Pharmaceutical preparations
This Intellectual Property Rights Agreement (“Agreement-) is made by and between DOCUCHEM SLU, a corporation duly organized under and pursuant to the laws of Spain having its principle place of business at Edifici Giroempren, Laboratori A.0.07 C/ Pic de Peguera, 11 17003 Girona. Spain (“DOCUCHEM”), and BioVie, Inc., a Nevada Corporation, and having its principal place of business at 11601 Wilshire Blvd, Suite 1100, Los Angeles, CA, USA (“BIOVIE”) (collectively “the Parties”),
FORM OF MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • January 26th, 2026 • Option Therapeutics Inc. • Pharmaceutical preparations • New York
This MANAGEMENT SERVICES AGREEMENT (this “Agreement”) is made and entered into as of [•], 2025 by and between Option Therapeutics Inc., a Delaware corporation (“Service Recipient”), and BioVie Inc., a Nevada corporation (“Parent”), effective as of completion of the Separation (as defined below) or such other date as Service Recipient and Parent may mutually agree upon in writing (the “Effective Time”). Service Recipient and Parent shall be referred to collectively as the “Parties” and, individually, as a “Party”.
ROYALTY AGREEMENTRoyalty Agreement • January 26th, 2026 • Option Therapeutics Inc. • Pharmaceutical preparations • New York
THIS ROYALTY AGREEMENT (the “Agreement”) dated as of April 11, 2016 (the “Effective Date”) by and between NanoAntibiotics, Inc., a Nevada corporation (the “Company”), LAT Pharma, LLC, an Illinois limited liability company (“LAT”), LAT Pharma Members (“LPM”), and The Barrett Edge, Inc., a New York corporation (“TBE”), (and, together with the Company, LAT, LPM and TBE, sometimes referred to herein individually as “Party” and collectively as the “Parties”).
FORM OF REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 16th, 2026 • Option Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of [•], 2026 by and between Option Therapeutics Inc., a Delaware corporation (“Option”), and BioVie Inc., a Nevada corporation (the “BioVie”). Option and BioVie are referred to together as the “Parties” and individually as a “Party.” Capitalized terms used herein shall have the respective meanings assigned to them in Article I or elsewhere in this Agreement.
ROYALTY AGREEMENTRoyalty Agreement • March 16th, 2026 • Option Therapeutics Inc. • Pharmaceutical preparations • New York
THIS ROYALTY AGREEMENT (the “Agreement”) dated as of April 11, 2016 (the “Effective Date”) by and between NanoAntibiotics, Inc., a Nevada corporation (the “Company”), LAT Pharma, LLC, an Illinois limited liability company (“LAT”), LAT Pharma Members (“LPM”), and The Barrett Edge, Inc., a New York corporation (“TBE”), (and, together with the Company, LAT, LPM and TBE, sometimes referred to herein individually as “Party” and collectively as the “Parties”).